window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'UA-108383172-1');

Novigenix Receives Reimbursement Coverage for Colox® in Switzerland

By |2019-10-09T09:09:47+02:009 October 2019|Communiqué de presse, Medical information, News Novigenix|

First liquid biopsy test reimbursed in Switzerland for colon cancer screening through private outpatient supplementary insurance product offered by Helsana LAUSANNE, SWITZERLAND - 07:00 CET, October  9, 2019  - Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine. today announced that Helsana, the leading health insurance

Read More

Novigenix Developing NGS Version of Early Colorectal Cancer Detection Test

By |2019-08-23T17:23:56+02:0017 May 2019|Medical information, News Novigenix|

NEW YORK (GenomeWeb) – With a new CEO at its helm, Swiss molecular diagnostic firm Novigenix is developing a new version of Colox, its mRNA-based assay for early colorectal cancer detection that applies next-generation sequencing instead of RT-PCR. The firm began a study earlier this year to validate the assay, which measures cancer-specific transcriptomic

Read More
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Learn more Ok

Privacy Notice

Go to Top